Cost effectiveness of cetuximab concurrent with radiotherapy for patients with locally advanced head and neck cancer in Taiwan: A decision-tree analysis

Agnes L F Chan, Henry W C Leung, Shiao Feng Huang

研究成果: 雜誌貢獻文章

6 引文 (Scopus)

摘要

Background: Concomitant chemotherapy with radiotherapy is considered to be the standard of care for patients with head and neck cancer and good performance status. However, published reports on the cost effectiveness of this therapeutic approach are extremely rare. Objective: The aim of this study was to estimate the cost effectiveness of cetuximab combined with radiotherapy compared with radiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck. Methods: A decision-tree analysis was used to compare cetuximab combined with radiotherapy and radiotherapy alone in the treatment of patients with locally advanced squamous cell carcinoma of the head and neck from the perspective of the national health payer (the Bureau of National Health Insurance [BNHI]) in Taiwan. The model was based on individual patient data extracted from an international phase III trial. The direct medical costs of care were estimated by clinical expert panels based on the reimbursement price of the BNHI (2007 values). One-way sensitivity analyses were performed while varying the costs and clinical parameters. Results: The incremental cost per quality-adjusted life-year (QALY) for patients receiving radiotherapy in combination with cetuximab compared with radiotherapy alone was $US36 992/QALY in the base-case analysis (2007 values). The sensitivity analysis showed the highest net benefit for radiotherapy alone if the cost of cetuximab increased by 50%. Conclusion: This study demonstrated that the addition of cetuximab to highdose radiotherapy regimens is likely to be cost effective in Taiwan because the incremental cost per QALYis below the commonly accepted cost-effectiveness threshold.
原文英語
頁(從 - 到)717-726
頁數10
期刊Clinical Drug Investigation
31
發行號10
DOIs
出版狀態已發佈 - 2011

指紋

Decision Trees
Decision Support Techniques
Head and Neck Neoplasms
Taiwan
Cost-Benefit Analysis
Radiotherapy
Costs and Cost Analysis
Quality-Adjusted Life Years
National Health Programs
Cetuximab
Standard of Care
Health Care Costs
Drug Therapy

ASJC Scopus subject areas

  • Pharmacology (medical)

引用此文

Cost effectiveness of cetuximab concurrent with radiotherapy for patients with locally advanced head and neck cancer in Taiwan : A decision-tree analysis. / Chan, Agnes L F; Leung, Henry W C; Huang, Shiao Feng.

於: Clinical Drug Investigation, 卷 31, 編號 10, 2011, p. 717-726.

研究成果: 雜誌貢獻文章

@article{83900bef332044b89cca8ecf88f6e0fe,
title = "Cost effectiveness of cetuximab concurrent with radiotherapy for patients with locally advanced head and neck cancer in Taiwan: A decision-tree analysis",
abstract = "Background: Concomitant chemotherapy with radiotherapy is considered to be the standard of care for patients with head and neck cancer and good performance status. However, published reports on the cost effectiveness of this therapeutic approach are extremely rare. Objective: The aim of this study was to estimate the cost effectiveness of cetuximab combined with radiotherapy compared with radiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck. Methods: A decision-tree analysis was used to compare cetuximab combined with radiotherapy and radiotherapy alone in the treatment of patients with locally advanced squamous cell carcinoma of the head and neck from the perspective of the national health payer (the Bureau of National Health Insurance [BNHI]) in Taiwan. The model was based on individual patient data extracted from an international phase III trial. The direct medical costs of care were estimated by clinical expert panels based on the reimbursement price of the BNHI (2007 values). One-way sensitivity analyses were performed while varying the costs and clinical parameters. Results: The incremental cost per quality-adjusted life-year (QALY) for patients receiving radiotherapy in combination with cetuximab compared with radiotherapy alone was $US36 992/QALY in the base-case analysis (2007 values). The sensitivity analysis showed the highest net benefit for radiotherapy alone if the cost of cetuximab increased by 50{\%}. Conclusion: This study demonstrated that the addition of cetuximab to highdose radiotherapy regimens is likely to be cost effective in Taiwan because the incremental cost per QALYis below the commonly accepted cost-effectiveness threshold.",
keywords = "Cetuximab, Cost-effectiveness, Head-and-neck-cancer, Radiotherapy, Squamous-cell-cancer",
author = "Chan, {Agnes L F} and Leung, {Henry W C} and Huang, {Shiao Feng}",
year = "2011",
doi = "10.2165/11588980-000000000-00000",
language = "English",
volume = "31",
pages = "717--726",
journal = "Clinical Drug Investigation",
issn = "1173-2563",
publisher = "Adis International Ltd",
number = "10",

}

TY - JOUR

T1 - Cost effectiveness of cetuximab concurrent with radiotherapy for patients with locally advanced head and neck cancer in Taiwan

T2 - A decision-tree analysis

AU - Chan, Agnes L F

AU - Leung, Henry W C

AU - Huang, Shiao Feng

PY - 2011

Y1 - 2011

N2 - Background: Concomitant chemotherapy with radiotherapy is considered to be the standard of care for patients with head and neck cancer and good performance status. However, published reports on the cost effectiveness of this therapeutic approach are extremely rare. Objective: The aim of this study was to estimate the cost effectiveness of cetuximab combined with radiotherapy compared with radiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck. Methods: A decision-tree analysis was used to compare cetuximab combined with radiotherapy and radiotherapy alone in the treatment of patients with locally advanced squamous cell carcinoma of the head and neck from the perspective of the national health payer (the Bureau of National Health Insurance [BNHI]) in Taiwan. The model was based on individual patient data extracted from an international phase III trial. The direct medical costs of care were estimated by clinical expert panels based on the reimbursement price of the BNHI (2007 values). One-way sensitivity analyses were performed while varying the costs and clinical parameters. Results: The incremental cost per quality-adjusted life-year (QALY) for patients receiving radiotherapy in combination with cetuximab compared with radiotherapy alone was $US36 992/QALY in the base-case analysis (2007 values). The sensitivity analysis showed the highest net benefit for radiotherapy alone if the cost of cetuximab increased by 50%. Conclusion: This study demonstrated that the addition of cetuximab to highdose radiotherapy regimens is likely to be cost effective in Taiwan because the incremental cost per QALYis below the commonly accepted cost-effectiveness threshold.

AB - Background: Concomitant chemotherapy with radiotherapy is considered to be the standard of care for patients with head and neck cancer and good performance status. However, published reports on the cost effectiveness of this therapeutic approach are extremely rare. Objective: The aim of this study was to estimate the cost effectiveness of cetuximab combined with radiotherapy compared with radiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck. Methods: A decision-tree analysis was used to compare cetuximab combined with radiotherapy and radiotherapy alone in the treatment of patients with locally advanced squamous cell carcinoma of the head and neck from the perspective of the national health payer (the Bureau of National Health Insurance [BNHI]) in Taiwan. The model was based on individual patient data extracted from an international phase III trial. The direct medical costs of care were estimated by clinical expert panels based on the reimbursement price of the BNHI (2007 values). One-way sensitivity analyses were performed while varying the costs and clinical parameters. Results: The incremental cost per quality-adjusted life-year (QALY) for patients receiving radiotherapy in combination with cetuximab compared with radiotherapy alone was $US36 992/QALY in the base-case analysis (2007 values). The sensitivity analysis showed the highest net benefit for radiotherapy alone if the cost of cetuximab increased by 50%. Conclusion: This study demonstrated that the addition of cetuximab to highdose radiotherapy regimens is likely to be cost effective in Taiwan because the incremental cost per QALYis below the commonly accepted cost-effectiveness threshold.

KW - Cetuximab

KW - Cost-effectiveness

KW - Head-and-neck-cancer

KW - Radiotherapy

KW - Squamous-cell-cancer

UR - http://www.scopus.com/inward/record.url?scp=80052476955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052476955&partnerID=8YFLogxK

U2 - 10.2165/11588980-000000000-00000

DO - 10.2165/11588980-000000000-00000

M3 - Article

C2 - 21744880

AN - SCOPUS:80052476955

VL - 31

SP - 717

EP - 726

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

SN - 1173-2563

IS - 10

ER -